2011年　IAAO

Theme：Strategy for Clinical Trial in Personalized Medicine

Greeting

Osamu Nagayama, Chairman Chugai Academy for Advanced Oncology

Opening Remarks

Bruce Chabner, MD Director of Clinical Research, Cancer Center Massachusetts General Hospital, Boston Massachusetts

▶ Symposium 1 Personalized medicine; Targeting ALK-fusion

Chair: Hiroyuki Mano, MD, PhD Jichi Medical University/Graduate School of Medicine, The University of Tokyo, Japan Nagahiro Saijo, MD, PhD Kinki University, School of Medicine, Japan

▶ S1-1. Discovery of EML4-ALK fusion oncogene

Speaker: Hiroyuki Mano, MD, PhD Professor of Medicine, Department of Medical Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo Professor of Medicine, Division of Functional Genomics, Jichi Medical University, Tochigi

▶ S1-2. Exploring for ALKoma with use of integrated diagnostic techniques

Speaker: Kengo Takeuchi, MD, PhD Project leader / Senior staff scientist, Pathology Project for Molecular Targets /Division of Pathology, The Cancer Institute Japanese Foundation for Cancer Research

▶ S1-3. Clinical trials with ALK inhibitor

Speaker: Pasi Antero Jänne, MD, PhD Associate Professor of Medicine, Dana-Farber Cancer Institute, USA

▶ S1-4. A large scale screening of ALK fusions

Speaker: A. John Iafrate, MD, PhD Associate Pathologist, Massachusetts General Hospital Associate Professor of Pathology, Department of Pathology, Harvard Medical School, USA

▶ Symposium 2 Synthetic lethality; Theory and Practice

Chair: Kiyohiko Hatake, MD, PhD Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan Yuko Kitagawa, MD, PhD Keio University School of Medicine, Japan

▶ S2-1. Some practical issues related to shRNA/siRNA screens in mammalian cells(cancelled)

▶ S2-2. Application of synthetic lethality to cancer therapy

Speaker: Christopher Lord, PhD Senior Staff Scientist, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, UK

▶ Special Lecture

“The Methodological Challenge of delivering personalised therapy for cancer patients”

Chair: Kiyohiko Hatake, MD, PhD Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan Nobuyuki Mizunuma,MD Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan   Speaker: Patrick G. Johnston, MD, PhD Dean, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University BelfastDirector, Institute of Health & Life Sciences, Queen’s University Belfast, UK

▶ Symposium3 Therapeutic Inhibition of oncogenic signaling

Chair: Masakazu Toi, MD, PhD Kyoto University School of Medicine, Japan Chikashi Ishioka, MD Tohoku University School of Medicine, Japan

▶ S3-1. PI3K pathway: Therapeutic targeting of malignancy

Speaker: Jose Baselga, MD, PhD Professor, Department of Medicine, Harvard Medical School Associate Director, MGH Cancer Center, Medicine, Massachusetts General Hospital Chief, Hematology/Oncology, Medicine, Massachusetts General Hospital, USA

▶ S3-2. Genetic predictors of RAF-dependence.

Speaker: David B. Solit, MD Elizabeth and Felix Rohatyn Chair for Junior Faculty, Memorial Sloan-Kettering Cancer Center, USA

▶ S3-3. Feedback and redundancy of oncogenic signaling pathways

Speaker: Neal Rosen, MD, PhD Enid A. Haupt Chair in Medical Oncology Member, Department of Medicine Member, Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, NY Professor of Pharmacology, Cornell University Graduate School of Medical Sciences, New York, NY Professor of Medicine, Joan and Sanford I. Weill Medical College, Cornell University, New York, NY, USA

Closing

Makoto Ogawa, MD Emeritus President, Aichi Cancer Center, Japan